The Claim
K1-70TM, administered as a single intravenous or intramuscular dose up to 150 mg, is well tolerated in adults with Graves' disease, with no serious adverse events, no immunogenic response in 83% of subjects, and no clinically significant injection site reactions.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A single dose of K1-70TM up to 150 mg given by injection into a vein or muscle is not associated with serious side effects, immune reactions in 83% of adults with Graves' disease, or significant reactions at the injection site.
See the scientific wording
K1-70TM, administered as a single intravenous or intramuscular dose up to 150 mg, is well tolerated in adults with Graves' disease, with no serious adverse events, no immunogenic response in 83% of subjects, and no clinically significant injection site reactions.
A specific antibody binds to the thyroid hormone receptor, stopping overactive signals that cause the thyroid to make too much hormone and the eyes to swell. This stops the excess hormone production and reduces eye swelling without triggering an immune reaction or causing local irritation.
What the research says
1 studyIn a small study, people with Graves' disease got one shot of K1-70TM and didn't have any serious side effects, their bodies didn't react against it, and their injection sites didn't swell or hurt much — so it seems safe.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.